BioSpace News Archive

Catalent, Inc., the leader in enabling the development and supply of better biopharmaceutical treatments for patients worldwide, announced several initiatives reflecting its ongoing commitment to strong corporate governance and shareholder value creation.

MBX Biosciences, Inc. announced that Kent Hawryluk, President and Chief Executive Officer, and Richard Bartram, Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12th, 2023, at 11:30 a.m. Eastern Time and will host 1-on-1 investor meetings.

Olink Holding AB, announced that Company management will participate in the following investor events.

Scale Biosciences, Inc. (ScaleBio™), an innovator in single cell sequencing leveraging combinatorial indexing technologies, today announced an expansion of their product portfolio to enable a broader range of single cell omics experiments and unlock new translational research applications.

Aldevron contributed to a publication in collaboration with 2020 Nobel Laureate Jennifer Doudna and the Innovative Genomics Institute (IGI) at the University of California, Berkeley to advance research on in vivo, CRISPR-based genome editing strategies to address genetic diseases of the central nervous system such as Huntington’s disease and ALS.

Phoenix Children’s, one of the nation’s fastest-growing pediatric healthcare systems, announced the promotion of Jared Muenzer, MD, MBA, to Chief Physician Executive.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced a positive Type C meeting with the U.S. Food and Drug Administration (“FDA”). Eagle and the FDA agreed on a path forward to advance the clinical development of EA-114, an estrogen receptor antagonist used in the treatment of breast cancer in post-menopausal women.

Oculis Holding AG announced second quarter and first half 2023 financial results for the period ended June 30, 2023, and an overview of the Company’s progress.

Entrada Therapeutics, Inc., a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle -therapeutics as a new class of medicines, announced the Company will participate in two investor conferences in September.

Omega Therapeutics, Inc. announced that Chris Schade has been appointed as Chairman of the Board, succeeding Noubar Afeyan, Ph.D. In addition, Michelle C. Werner will join Omega’s Board to support the Company’s growth.